Search results
AbbVie (ABBV) Gets FDA Rejection for Parkinson's Candidate
Zacks via Yahoo Finance· 1 year agoAbbVie ABBV announced that FDA has issued a complete response letter (CRL) to its new drug...
AbbVie (ABBV) to Report Q4 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 1 year agoAbbVie's (ABBV) Q4 performance will likely reflect strong drug demand from its immunology and...
AbbVie's (ABBV) Rinvoq Gets CHMP Nod for New Indication
Zacks via Yahoo Finance· 2 years agoAbbVie Inc. ABBV announced that the European Medicines Agency’s Committee for Medicinal Products for...
Can AbbVie (ABBV) Protect Revenues After Humira Patent Loss?
Zacks via Yahoo Finance· 10 months agoAbbVie’s ABBV key blockbuster immunology medicine, Humira lost patent protection in the United...
AbbVie (ABBV) Beats Q4 Earnings Estimates, Misses on Sales
Zacks via Yahoo Finance· 1 year agoAbbVie Inc. ABBV reported adjusted earnings of $3.60 per share for the fourth quarter of 2022,...
AbbVie (ABBV) to Acquire ImmunoGen (IMGN) for $10.1 Billion
Zacks via Yahoo Finance· 6 months agoAbbVie (ABBV) offers to buy ImmunoGen (IMGN) for approximately $10.1 billion, which will diversify...
Will AbbVie's (ABBV) New Drugs Continue to Drive Q4 Earnings?
Zacks via Yahoo Finance· 1 year agoAbbVie’s ABBV fourth-quarter revenues are likely to be driven by revenues generated from the sales...
AbbVie (ABBV) Outperforms Industry This Year So Far: Here's Why
Zacks via Yahoo Finance· 2 years agoAbbVie (ABBV) has several new drugs with the potential to drive revenues once Humira loses U.S....
AbbVie's (NYSE:ABBV) investors will be pleased with their favorable 80% return over the last three...
Simply Wall St. via Yahoo Finance· 1 year agoAbbVie Inc. (NYSE:ABBV) shareholders have seen the share price descend 13% over the month. But don't...
AbbVie (ABBV) Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU
Zacks via Yahoo Finance· 6 days agoAbbVie (ABBV) announces that the EMA's CHMP issued a positive opinion on its regulatory filing...